A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel. Revised Protocol 05 incorporating Protocol Amendment
Read time: 1 mins
Last updated:13th Jul 2009
To compare overall survival of subjects with castration resistant prostate cancer (CRPC), that have progressed during or following docetaxel treatment, when randomized to treatment with bone-directed radiotherapy followed by ipilimumab vs bone-directed radiotherapy followed by placebo.
|Study start date||2009-07-13|